Judith J. Gout-Zwart

Trends in direct oral anticoagulant (DOAC) use: health benefits and patient preference.

Lisa A. de Jong, Mike Koops, Judith J. Gout-Zwart et al. · PubMed · 2018 · 30 citations

Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The Netherlands

Judith J. Gout-Zwart, Lisa A. de Jong, Lisanne Saptenno et al. · PharmacoEconomics - Open · 2019 · 14 citations · Full text

A Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline Pharmacotherapy

E.J.J. Berm, Judith J. Gout-Zwart, Jos Luttjeboer et al. · PLoS ONE · 2016 · 11 citations · Full text

Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis

Lisa A. de Jong, Judith J. Gout-Zwart, Marina van den Bosch et al. · Journal of Medical Economics · 2019 · 11 citations · Full text

Budget Impact Analysis of a Renal Point-of-Care Test in Dutch Community Pharmacies to Prevent Antibiotic-Related Hospitalizations

Judith J. Gout-Zwart, Erien H. J. Olde Hengel, Petra Hoogland et al. · Applied Health Economics and Health Policy · 2018 · 10 citations · Full text